Pregabalin in patients with primary brain tumors and seizures: a preliminary observation.
Détails
ID Serval
serval:BIB_EB3748B39386
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Pregabalin in patients with primary brain tumors and seizures: a preliminary observation.
Périodique
Clinical neurology and neurosurgery
ISSN
1872-6968 (Electronic)
ISSN-L
0303-8467
Statut éditorial
Publié
Date de publication
02/2009
Peer-reviewed
Oui
Volume
111
Numéro
2
Pages
171-173
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: ppublish
Publication Status: ppublish
Résumé
Patients with brain tumors and seizures should be treated with non-enzyme-inducing antiepileptic drugs (AED). Some of the newer drugs seem particularly suited in these patients.
Here we describe our experience with pregabalin (PGB); its effectiveness was retrospectively studied in nine consecutive patients with primary brain tumors and seizures.
Six subjects had secondarily generalized and three simple partial seizures. Patients mostly suffered from WHO grade IV gliomas. PGB replaced enzyme inducing, inefficacious or bad tolerated AED, as add-on or monotherapy. Median follow-up was 5 (2-19) months; three patients died of their tumor. Daily median dosage was 300 mg. All subjects experienced at least a 50% seizure reduction, six were seizure-free. Side effects were reported in four patients, leading to PGB discontinuation in two.
PGB appears to have a promising effectiveness in this setting, even as a monotherapy. Based on these results we embarked on a prospective controlled trial.
Here we describe our experience with pregabalin (PGB); its effectiveness was retrospectively studied in nine consecutive patients with primary brain tumors and seizures.
Six subjects had secondarily generalized and three simple partial seizures. Patients mostly suffered from WHO grade IV gliomas. PGB replaced enzyme inducing, inefficacious or bad tolerated AED, as add-on or monotherapy. Median follow-up was 5 (2-19) months; three patients died of their tumor. Daily median dosage was 300 mg. All subjects experienced at least a 50% seizure reduction, six were seizure-free. Side effects were reported in four patients, leading to PGB discontinuation in two.
PGB appears to have a promising effectiveness in this setting, even as a monotherapy. Based on these results we embarked on a prospective controlled trial.
Mots-clé
Adult, Aged, Anticonvulsants/administration & dosage, Anticonvulsants/adverse effects, Anticonvulsants/therapeutic use, Brain Neoplasms/drug therapy, Brain Neoplasms/physiopathology, Epilepsies, Partial/drug therapy, Epilepsies, Partial/physiopathology, Female, Follow-Up Studies, Glioma/drug therapy, Glioma/physiopathology, Humans, Male, Middle Aged, Pregabalin, Retrospective Studies, Seizures/drug therapy, Seizures/physiopathology, Treatment Outcome, gamma-Aminobutyric Acid/administration & dosage, gamma-Aminobutyric Acid/adverse effects, gamma-Aminobutyric Acid/analogs & derivatives, gamma-Aminobutyric Acid/therapeutic use
Pubmed
Web of science
Création de la notice
12/03/2009 14:22
Dernière modification de la notice
14/05/2024 8:06